Clinical trial Recruiting at 1 site Interventional

Comparing two ways to wean preterm babies from high-frequency oscillatory ventilation

Official title: Randomized Controlled Trial of Two Protocols for Weaning From High Frequency Oscillatory Ventilation in Preterm Neonates With Respiratory Distress Syndrome

Run by Mansoura University Children Hospital · NCT07202299 · Data updated 2026-11-12

This trial tests two different methods to stop high-frequency oscillatory ventilation in preterm infants with respiratory distress syndrome to see which leads to fewer complications.

Quick facts

Study typeInterventional
SexAll
Enrollment110 (estimated)
SponsorMansoura University Children Hospital
Academic / other
Locations1 site (Al Mansurah)
StatusRecruiting
StartedSeptember 22, 2025
Main results expectedMarch 2027
Study endsSeptember 2027
Registry record updatedOctober 1, 2025
Trial IDNCT07202299 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Preterm infants (gestational age ≤34 weeks) with respiratory distress syndrome who required HFOV for more than 24 hours after failing noninvasive respiratory support are eligible.

Probably not a fit

Infants with major congenital malformations, chromosomal abnormalities, inborn errors of metabolism, or severe intraventricular hemorrhage (grade III/IV) are excluded and would not be expected to benefit from the trial protocol results.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label randomized trial enrolling preterm infants (≤34 weeks gestation) with respiratory distress syndrome who have been on high-frequency oscillatory ventilation (HFOV) for more than 24 hours after failure of noninvasive support. Enrolled infants are randomly assigned to one of two predefined HFOV weaning protocols and managed in the NICU at Mansoura University Children Hospital. Outcomes will include measures of successful weaning, duration of mechanical support, and frequency of complications such as apnea, hypoxemia, or need to return to HFOV. The trial aims to identify a practical weaning approach that minimizes ventilation time and adverse events in this population.

Why it matters

Potential benefit: If successful, the preferred protocol could shorten time on HFOV and reduce complications for preterm infants with respiratory distress syndrome.

How similar studies have gone: There are limited randomized trials comparing HFOV weaning protocols and some observational reports support protocolized weaning, but high-quality evidence is still sparse.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Preterm infants with RDS whose gestational age is 34 weeks or less who required HFOV for more than 24 hours duration due to failure of non- invasive respiratory support due to any of the following:

  1. Severe hypercapnea PaCO2 \> 60 mmHg associated with pH \< 7.25.
  2. Hypoxemia PaO2 \< 50 mmHg, with FiO2 \> 40%.
  3. Frequent apneas: 6 or more episodes of apnea requiring mild or moderate stimulation within 6-hour period or one apneic episode requiring bag and mask positive pressure ventilation.

Exclusion Criteria:

Preterm infants with any of the following :

1. Major congenital malformations or chromosomal aberrations.
2. Inborn errors of metabolism.
3. Severe intraventricular hemorrhage (IVH) grade III or IV

Where it's running

  • Mansoura University Children Hospital
    Al Mansurah, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.